Product Information
Registration Status: ActiveRIFAREN 150 CAPSULE 150mg is approved to be sold in Singapore with effective from 1988-04-21. It is marketed by GOLDPLUS UNIVERSAL PTE LTD, with the registration number of SIN00312P.
This product contains Rifampicin 150mg in the form of CAPSULE. It is approved for ORAL use.
This product is manufactured by REMEDICA LTD in CYPRUS.
It is a Prescription Only Medicine that can only be obtained from a doctor or a dentist, or a pharmacist with a prescription from a Singapore-registered doctor or dentist.
Description
A semisynthetic antibiotic produced from Streptomyces mediterranei. It has a broad antibacterial spectrum, including activity against several forms of Mycobacterium. In susceptible organisms it inhibits DNA-dependent RNA polymerase activity by forming a stable complex with the enzyme. It thus suppresses the initiation of RNA synthesis. Rifampin is bactericidal, and acts on both intracellular and extracellular organisms. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p1160)
Indication
For the treatment of Tuberculosis and Tuberculosis-related mycobacterial infections.
Mechanism of Action
Rifampin acts via the inhibition of DNA-dependent RNA polymerase, leading to a suppression of RNA synthesis and cell death.
Pharmacokinetics
- Absorption
- Well absorbed from gastrointestinal tract.
- Distribution
- Metabolism
- Primarily hepatic, rapidly deacetylated.
- Elimination
Clearance
* 0.19 +/- 0.06 L/hr/kg [300 mg IV] * 0.14 +/- 0.03 L/hr/kg [600 mg IV]
Toxicity
LD50=1570 mg/kg (rat), chronic exposure may cause nausea and vomiting and unconsciousness
Active Ingredient/Synonyms
3-(((4-Methyl-1-piperazinyl)imino)methyl)rifamycin SV | RFP | Rifampicina | Rifampicinum | Rifampin | Rifampicin |
Source of information: Drugbank (External Link). Last updated on: 3rd July 18. *Trade Name used in the content below may not be the same as the HSA-registered product.